Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

29. April 2025 08:30 ET | Quelle: AP Biosciences

AP Biosciences Presents Preclinical Data on p95HER/CD137 T-Cell Engager at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 29, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...
22. April 2025 08:30 ET | Quelle: AP Biosciences

AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients

TAIPEI, Taiwan, April 22, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of innovative bispecific...
21. April 2025 23:37 ET | Quelle: AP Biosciences

UPDATE -- AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...
21. April 2025 08:30 ET | Quelle: AP Biosciences

AP Bioscience to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today...